Intravitreal bevacizumab (Avastin TM) Safety Survey
Many of us are interested in knowing the benefits as well as the risks from using intravitreal bevacizumab (Avastin TM). As this technique becomes more widely used, it is important that we create a communication system to collect information about intravitreal-bevacizumab (Avastin TM)-associated adverse events occurring worldwide.
Your participation in this survey will help establish a body of knowledge regarding safety issues surrounding the use of intravitreal bevacizumab (Avastin TM).
The following three pages briefly request this information:
Page 1 – institution/group demographic information
Page 2 – summary of total injections, total patients treated, adverse events
(AEs)
Page 3 – brief follow-up information on each AE reported
Thank you!
Anne Fung, MD
Philip Rosenfeld, MD PhD
Elias Reichel, MD
Please contact Anne Fung, MD with questions or comments:
Work 415 923 3918
Mailing address: 2100 Webster Street, Suite 214
San Francisco, CA 94115
If you have already submitted data and wish to amend only a few items, please
email Anne Fung, MD with the changes. Thank you.
If this online survey is useful, we may establish login IDs at a later date.
Until then, please individually email your comments to the address above.
To protect contributing physicians and our patients, all information submitted through this website will be transmitted via a secure server directly into our databases. Once we have confirmed that no duplication in data has occurred, your identifying information will be removed from these data. Since we are collecting information about adverse events, we will also protect you by never publishing or presenting your name in association with these data. This survey is ssupported by the Pacific Vision Foundation. Genentech Inc. has not participated in the development nor funding of this survey. |
|